Literature DB >> 2815978

Microparticles as potentially orally active immunological adjuvants.

D T O'Hagan1, K Palin, S S Davis, P Artursson, I Sjöholm.   

Abstract

A model microparticulate carrier system, capable of partially protecting an entrapped antigen against enzymatic degradation, has been successfully used to induce an enhanced secretory immune response to an incorporated model soluble antigen following oral administration to experimental rats. Ovalbumin was incorporated into polyacrylamide microparticles (2.55 microns diameter) and administered orally on four consecutive days to rats primed 14 days earlier by intraperitoneal injection. The memory secretory IgA antibody response (day 65) to the microparticle incorporated antigen group was significantly raised relative to a soluble antigen control group response (p less than 0.01), following administration of a booster dose of soluble antigen to both groups (day 61).

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2815978     DOI: 10.1016/0264-410x(89)90156-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  A macromolecular delivery vehicle for protein-based vaccines: acid-degradable protein-loaded microgels.

Authors:  Niren Murthy; Mingcheng Xu; Stephany Schuck; Jun Kunisawa; Nilabh Shastri; Jean M J Fréchet
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-18       Impact factor: 11.205

2.  Biodegradable microparticles as controlled release antigen delivery systems.

Authors:  D T O'Hagan; D Rahman; J P McGee; H Jeffery; M C Davies; P Williams; S S Davis; S J Challacombe
Journal:  Immunology       Date:  1991-06       Impact factor: 7.397

3.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.

Authors:  S J Challacombe; D Rahman; H Jeffery; S S Davis; D T O'Hagan
Journal:  Immunology       Date:  1992-05       Impact factor: 7.397

Review 5.  Oral delivery of vaccines. Formulation and clinical pharmacokinetic considerations.

Authors:  D T O'Hagan
Journal:  Clin Pharmacokinet       Date:  1992-01       Impact factor: 6.447

6.  Microencapsulation of hepatitis B core antigen for vaccine preparation.

Authors:  T Uchida; K Shiosaki; Y Nakada; K Fukada; Y Eda; S Tokiyoshi; N Nagareya; K Matsuyama
Journal:  Pharm Res       Date:  1998-11       Impact factor: 4.200

7.  Targeting to intestinal M cells.

Authors:  M A Jepson; M A Clark; N Foster; C M Mason; M K Bennett; N L Simmons; B H Hirst
Journal:  J Anat       Date:  1996-12       Impact factor: 2.610

8.  Immunological properties of hepatitis B core antigen fusion proteins.

Authors:  M J Francis; G Z Hastings; A L Brown; K G Grace; D J Rowlands; F Brown; B E Clarke
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

9.  From allergen to oral vaccine carrier: A new face of ragweed pollen.

Authors:  Md Jasim Uddin; Harvinder Singh Gill
Journal:  Int J Pharm       Date:  2018-05-03       Impact factor: 5.875

10.  The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique.

Authors:  H Jeffery; S S Davis; D T O'Hagan
Journal:  Pharm Res       Date:  1993-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.